Literature DB >> 20551057

pp60c-Src phosphorylates and activates vacuolar protein sorting 34 to mediate cellular transformation.

Dianne S Hirsch1, Yi Shen, Milos Dokmanovic, Wen Jin Wu.   

Abstract

Vacuolar protein sorting 34 (VPS34) contributes to the regulation of the mammalian target of rapamycin complex 1/S6 kinase 1 pathway downstream of nutrient signaling. However, intracellular mechanisms leading to VPS34 activation remain unclear. Here, we report that Src directly phosphorylates VPS34, and that this phosphorylation activates VPS34 lipid kinase activity, leading to Src-Y527F-mediated cellular transformation. Silencing endogenous VPS34 specifically inhibits Src-Y527F-induced colony formation in soft agar, but not Ras-G12V-induced colony formation. We have identified two novel hVPS34 mutations, which either eliminate lipid kinase activity (kinase-dead mutant) or reduce tyrosine phosphorylation by Src-Y527F. When kinase-dead mutant of hVPS34 is stably expressed in Src-Y527F-transformed cells, transformation activities are blocked, indicating that the lipid kinase activity of hVPS34 is essential for Src-mediated cellular transformation. Furthermore, stable expression of this hVPS34 kinase-dead mutant causes an increased number of binucleate and multinucleate cells, suggesting that the kinase activity of hVPS34 is also required for cytokinesis. Moreover, when the hVPS34 mutant that has reduced tyrosine phosphorylation by Src is stably expressed in Src-Y527F-transformed cells, Src-Y527F-stimulated colony formation is also reduced. Data presented here provide important evidence that VPS34 lipid kinase activity could be positively regulated by Src-mediated tyrosine phosphorylation in mammalian cells. This finding highlights a previously unappreciated relationship between VPS34, a class III phosphatidylinositol-3-kinase, and Src non-receptor tyrosine kinase. Additionally, we find that the levels of VPS34 expression and tyrosine phosphorylation are correlated with the tumorigenic activity of human breast cancer cells, indicating that Src to VPS34 signaling warrants further investigation as a pathway contributing to the development and progression of human cancers. (c)2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20551057     DOI: 10.1158/0008-5472.CAN-09-2682

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

Review 1.  The myotubularin family of lipid phosphatases in disease and in spermatogenesis.

Authors:  Dolores D Mruk; C Yan Cheng
Journal:  Biochem J       Date:  2011-01-15       Impact factor: 3.857

Review 2.  PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting.

Authors:  Lauren M Thorpe; Haluk Yuzugullu; Jean J Zhao
Journal:  Nat Rev Cancer       Date:  2015-01       Impact factor: 60.716

Review 3.  PI3K isoform-selective inhibitors: next-generation targeted cancer therapies.

Authors:  Xiang Wang; Jian Ding; Ling-hua Meng
Journal:  Acta Pharmacol Sin       Date:  2015-09-14       Impact factor: 6.150

4.  VPS34 regulates TSC1/TSC2 heterodimer to mediate RheB and mTORC1/S6K1 activation and cellular transformation.

Authors:  Nishant Mohan; Yi Shen; Milos Dokmanovic; Yukinori Endo; Dianne S Hirsch; Wen Jin Wu
Journal:  Oncotarget       Date:  2016-08-09

5.  VPS34 stimulation of p62 phosphorylation for cancer progression.

Authors:  X Jiang; Y Bao; H Liu; X Kou; Z Zhang; F Sun; Z Qian; Z Lin; X Li; X Liu; L Jiang; Y Yang
Journal:  Oncogene       Date:  2017-08-28       Impact factor: 9.867

6.  Protrudin-mediated ER-endosome contact sites promote MT1-MMP exocytosis and cell invasion.

Authors:  Nina Marie Pedersen; Eva Maria Wenzel; Ling Wang; Sandra Antoine; Philippe Chavrier; Harald Stenmark; Camilla Raiborg
Journal:  J Cell Biol       Date:  2020-08-03       Impact factor: 10.539

Review 7.  The Role of Phosphatidylinositol 3-Kinase Catalytic Subunit Type 3 in the Pathogenesis of Human Cancer.

Authors:  Chien-An Chu; Yi-Wen Wang; Yi-Lin Chen; Hui-Wen Chen; Jing-Jing Chuang; Hong-Yi Chang; Chung-Liang Ho; Chen Chang; Nan-Haw Chow; Chung-Ta Lee
Journal:  Int J Mol Sci       Date:  2021-10-11       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.